Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger EntityMay 1, 2024
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 April 15, 2024
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) ToolkitMarch 5, 2024
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement FinancingJanuary 2, 2024